Tiziana Life Sciences PLC has appointed a vice-president of regulatory affairs. Dr Kevin Shutz, who has 19 years pharma industry experience, 14 of them in the regulatory field, will lead clinical trial ‘interactions’ with drug watchdogs in the US, Europe and Asia.
Galantas Gold Corporation received notification that on 17 June and 18 June chief executive Mario Stifano bought 12,000 shares at an average price of C$0.71 apiece.